V
V. Picone
Publications - 7
Citations - 1133
V. Picone is an academic researcher. The author has contributed to research in topics: Irinotecan & Internal medicine. The author has an hindex of 2, co-authored 4 publications receiving 1029 citations.
Papers
More filters
Journal ArticleDOI
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
Alfredo Falcone,Sergio Ricci,Isa Brunetti,Elisabetta Pfanner,Giacomo Allegrini,C. Barbara,Lucio Crinò,Giovanni Benedetti,W. Evangelista,Laura Fanchini,Enrico Cortesi,V. Picone,Stefano Vitello,Silvana Chiara,Cristina Granetto,Gianfranco Porcile,Luisa Fioretto,Cinzia Orlandini,Michele Andreuccetti,Gianluca Masi +19 more
TL;DR: The FOLFOXIRI regimen improves RR, PFS, and OS compared with FOLFIRI, with an increased, but manageable, toxicity in patients with metastatic colorectal cancer with favorable prognostic characteristics.
Journal ArticleDOI
The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)
Alfredo Falcone,Gianluca Masi,Isa Brunetti,Giovanni Benedetti,O. Bertetto,V. Picone,Silvana Chiara,Marco Merlano,Stefano Vitello,S. Ricci +9 more
TL;DR: The FOLFOXIRI regimen is feasible with manageable toxicities and significantly increases RR, R0 resection of mts, PFS and overall S compared to FOLFIRI, and increased activity allowed a radical secondary resection in a greater percentage of patients in the FOL FOXIRI arm.
Randomized phase III study of FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) vs FOLFIRI (irinotecan and 5FU/LV) as first-line treatment of metastatic colorectal cancer (MCRC): Subgroup and multivariate analysis
Alfredo Falcone,Michele Andreuccetti,Cinzia Orlandini,C. Barbara,Giovanni Benedetti,W. Evangelista,V. Picone,Silvana Chiara,Cristina Granetto,G.Masi Gmasi +9 more
Journal ArticleDOI
Intensified Total Neoadjuvant Therapy Versus Intensified Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer: A Propensity Score Matching Analysis
Francesca De Felice,Daniela Musio,Franco Iafrate,Salvatore Caponnetto,V. Picone,Giancarlo D'Ambrosio,Fabio Massimo Magliocca,Francesca Tozzi,Giorgio De Toma,Vincenzo Tombolini,Enrico Cortesi +10 more
TL;DR: Intensified TNT and CRT resulted in similar survival outcomes, while intensified TNT led to higher pCR, albeit not statistically significant.
Journal ArticleDOI
Phase II study of sequential chemotherapy with cisplatin (P) in combination with infusional 5FU/LV (PFL) followed by irinotecan (Ir) + 5FU/LV (IrFL) followed by docetaxel (T) + 5FU/LV (TFL) in patients (pts) with metastatic gastric carcinoma (MGC) by the Gruppo Oncologio Nord-Ovest (GONO)
Fotios Loupakis,Gianluca Masi,S. Bursi,V. Picone,L. Mentuccia,Cristina Granetto,E. Fea,R. Murr,Andrea Antonuzzo,Alfredo Falcone +9 more
TL;DR: In this paper, 5FU in combination with P can be considered a standard treatment for MGC, and the combination of Ir and T with P and 5FU is considered as a treatment option.